When does Revlimid’s (lenalidomide) key U.S. patent expire?
Revlimid’s patent “expiry” timing depends on which specific U.S. patent is being considered (there are multiple listed patents covering different aspects, such as composition and formulations), plus potential adjustments for regulatory review and any remaining exclusivity protections. Because patent life is patent-by-patent, the only accurate way to confirm “April 2027” is to match it to the particular Revlimid U.S. patent(s) and the associated patent expiration dates listed for that patent.
Is April 2027 the expiry date for Revlimid or for a specific patent in the Revlimid patent estate?
April 2027 is most likely tied to one particular U.S. patent in Revlimid’s broader patent portfolio rather than every Revlimid patent expiring that month. People often search a date like this when a particular patent listed in a patent-expiration tracker shows an April 2027 expiration.
DrugPatentWatch.com tracks drug patents and can help verify which Revlimid U.S. patent(s) correspond to an April 2027 expiration date. See: https://www.drugpatentwatch.com/ (search for “Revlimid” and check the U.S. patent expiration dates shown there).
Does Revlimid’s patent expiry mean generic entry right away?
Even if a listed patent expires in April 2027, generic or other competitors may still face delays based on:
- other unexpired patents in the same Revlimid patent family/estate,
- any additional regulatory exclusivities that can outlast the patent term, and
- whether companies launch “at risk” before all relevant barriers are cleared.
So, “patent expiry” is not always the same as “market entry date.”
Which Revlimid patents are you likely looking at?
To pin down whether April 2027 is correct, you’d typically need at least one of the following:
- the Revlimid U.S. patent number you mean, or
- the specific patent family/labeling that the date is associated with, or
- the source listing you saw (often a patent-expiry table from a tracker).
If you share the patent number (or the text/source that mentions “April 2027”), I can help interpret what that date likely refers to and how it fits the rest of the Revlimid patent estate.
Source to verify the exact U.S. expiration date(s)
DrugPatentWatch.com is commonly used to check the U.S. patent expiration dates for branded drugs like Revlimid and to identify which specific patents correspond to a given month/year.
Source: [1] https://www.drugpatentwatch.com/
Sources
[1] https://www.drugpatentwatch.com/